Medtronic wants $6m for legal fees in Mirowski spat

Medtronic (NYSE:MDT) asked a federal court for a $6 million award to cover its legal costs in the long-running battle with Mirowski Family Ventures involving patents licensed to Boston Scientific (NYSE:BSX). A federal judge in Delaware ruled in June that MFV must cover legal costs in the case, which made it all the way to the U.S. Supreme Court last year. Judge Susan Robinson of the U.S. District Court for Delaware ruled that MFV must cover the legal costs in the case, according to court documents. Last week Medtronic asked Robinson to award more than $6 million in fees, “reflecting the amounts paid by Medtronic litigating this action from August 2007 through June 2015,” according to court documents. “These are amounts billed by Robins Kaplan, lead counsel in this matter, and WilmerHale, whose attorneys were retained to represent Medtronic at the United States Supreme Court,” according to the filings. MFV represents the estate of Dr. Michel Mirowski, who helped invent the implantable defibrillator. The group, which controls several patents related to implantable cardioverter defibrillators and cardiac resynchronization therapy devices, has been pursuing patent infringement cases against both Medtronic, Guidant and successor Boston Scientific for years. Last week Judge Susan Robinson of the U.S. District Court for Delaware ruled that MFV must cover the legal costs in the case, according to court documents. In...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiovascular Legal News Cardiac Rhythm Management medtronic Mirowski Family Ventures Source Type: news

Related Links:

Authors: Bonios MJ, Adamopoulos SN, Drakos SG PMID: 32464278 [PubMed - as supplied by publisher]
Source: Hellenic Journal of Cardiology - Category: Cardiology Tags: Hellenic J Cardiol Source Type: research
The long-term effect of tricuspid regurgitation (TR) after device implantation on long-term mortality remains unknown. In the present study, we sought to examine whether patients undergoing an implantable cardiac device procedure (pacemaker, cardiac defibrillator or cardiac resynchronisation therapy) have an increased risk of TR and to determine the effect of this on long-term survival.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Providers should be aware of the possibility of cardiac resynchronization therapy ‐related proarrhythmia which could be life‐threatening. His‐bundle pacing may serve as an alternative, more physiological, option in the management as it preserves the normal sequence of depolarization from the septum to the lateral wall, and from endocardium to epicardium. AbstractProviders should be aware of the possibility of cardiac resynchronization therapy ‐related proarrhythmia which could be life‐threatening. His‐bundle pacing may serve as an alternative, more physiological, option in the management as it preserves the nor...
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
Source: Journal of Nuclear Cardiology - Category: Nuclear Medicine Source Type: research
AbstractPurpose of reviewIn this review article, we aim to describe the pathophysiology of concomitant atrial fibrillation and both left and right heart failure, as well as pronounce the prognosis of having these two conditions simultaneously. This review also summarizes the current management of atrial fibrillation including stroke and thromboembolism prevention in the presence of systolic and diastolic heart failure.Recent findingsWhile rhythm control strategy is not superior to rate control strategy in atrial fibrillation patients without heart failure, catheter ablation for atrial fibrillation has shown to improve outc...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
ConclusionsIn CRT devices with left ventricular sensing, LA signal could be detected and used to estimate IACT especially if long ‐spaced electrodes are used.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - Category: Cardiology Authors: Tags: DEVICES Source Type: research
Myocardial scarring is associated with non-response to cardiac resynchronization therapy (CRT) and conduction delay. Little is known about the significance and cause of left ventricular (LV) paced conduction disturbance (LPCD).
Source: Heart Rhythm - Category: Cardiology Authors: Source Type: research
Recent studies suggest that circulating endothelial progenitor cells (EPCs) may influence the response to cardiac resynchronization therapy (CRT). The aim of this study was to evaluate the effect of CRT on EPC...
Source: Stem Cell Research and Therapy - Category: Stem Cells Authors: Tags: Research Source Type: research
CONCLUSIONS: Triage-HF effectively stratified Japanese patients at risk of HF-related hospitalization. PMID: 32448844 [PubMed - as supplied by publisher]
Source: Circulation Journal - Category: Cardiology Authors: Tags: Circ J Source Type: research
AbstractPurpose of ReviewBiomarkers of cardiac fibrosis closely track the disease state that gives rise to heart failure. The purpose of this review is to highlight recent data on the use of soluble ST2, galectin-3, and procollagen, three markers of cardiac fibrosis, for aiding with prognostication, and to explore the use of these biomarkers for guiding therapy.Recent FindingsSoluble ST2, galectin-3, and procollagen are prognostic in both acute and chronic heart failure, and data are emerging as to their potential uses for guiding therapies. Mortality benefit from exercise, cardiac resynchronization therapy, statin use, as...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
More News: Cardiac Resynchronization Therapy | Cardiology | Cardiovascular | Heart | Legislation | Medical Devices